Europe — EMA
Milrinon Stragen (Milrinone)
GNH USA supplies Milrinon Stragen (Milrinone), a phosphodiesterase‑3 inhibitor for decompensated heart failure and cardiogenic shock.
Request sourcing
What is Milrinone?
Milrinone, the active ingredient in Milrinon Stragen, is a Phosphodiesterase 3 inhibitor presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients. GNH USA supplies Milrinon Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Milrinone used for?
Milrinone acts as a cardiac inotropic and vasodilator agent, improving heart performance in critical care settings.
Acute decompensated heart failure: enhances cardiac output and reduces pulmonary congestion. Cardiogenic shock: provides rapid inotropic support and systemic vasodilation to stabilize blood pressure.
What are the side effects of Milrinone?
Milrinone may cause a range of adverse reactions that clinicians monitor during therapy.
Common Side Effects: - Hypotension - Tachycardia - Headache - Nausea - Flushing - Arrhythmias (non‑sustained)
Serious or Rare Side Effects: - Severe hypotension leading to organ hypoperfusion - Ventricular arrhythmias or sudden cardiac death - Myocardial ischemia - Severe allergic reactions (anaphylaxis) - Thrombocytopenia
What precautions apply to Milrinone?
Milrinone requires careful monitoring and specific safety measures before and during administration.
Monitor blood pressure: watch for excessive hypotension. Monitor cardiac rhythm: detect arrhythmias promptly. Adjust dose in renal impairment: reduced clearance may increase exposure. Use cautiously after recent myocardial infarction: risk of ischemia. Avoid in uncontrolled arrhythmias: may exacerbate rhythm disturbances. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Milrinone interact with?
Milrinone can interact with several drug classes, influencing its safety and efficacy.
Major Interactions (Avoid): - Concomitant use with other phosphodiesterase‑3 inhibitors: additive vasodilation and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase milrinone plasma levels. - Potent vasodilators (e.g., nitroprusside, nitroglycerin): risk of severe hypotension.
Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response. - Diuretics: can potentiate volume depletion and hypotension. - Digoxin: monitor for arrhythmias when both are used.
